Literature DB >> 27062290

ESX-1 exploits type I IFN-signalling to promote a regulatory macrophage phenotype refractory to IFNγ-mediated autophagy and growth restriction of intracellular mycobacteria.

Julia Lienard1, Elin Movert1, Christine Valfridsson1, Erik Sturegård2, Fredric Carlsson3.   

Abstract

The ability of macrophages to eradicate intracellular pathogens is normally greatly enhanced by IFNγ, a cytokine produced mainly after onset of adaptive immunity. However, adaptive immunity is unable to provide sterilizing immunity against mycobacteria, suggesting that mycobacteria have evolved virulence strategies to inhibit the bactericidal effect of IFNγ-signalling in macrophages. Still, the host-pathogen interactions and cellular mechanisms responsible for this feature have remained elusive. We demonstrate that the ESX-1 type VII secretion systems of Mycobacterium tuberculosis and Mycobacterium  marinum exploit type I IFN-signalling to promote an IL-12(low) /IL-10(high) regulatory macrophage phenotype characterized by secretion of IL-10, IL-27 and IL-6. This mechanism had no impact on intracellular growth in the absence of IFNγ but suppressed IFNγ-mediated autophagy and growth restriction, indicating that the regulatory phenotype extends to function. The IFNγ-refractory phenotype was partly mediated by IL-27-signalling, establishing functional relevance for this downstream cytokine. These findings identify a novel macrophage-modulating function for the ESX-1 secretion system that may contribute to suppress the efficacy of adaptive immunity and provide mechanistic insight into the antagonistic cross talk between type I IFNs and IFNγ in mycobacterial infection.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27062290     DOI: 10.1111/cmi.12594

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  8 in total

Review 1.  The crucial roles of Th17-related cytokines/signal pathways in M. tuberculosis infection.

Authors:  Hongbo Shen; Zheng W Chen
Journal:  Cell Mol Immunol       Date:  2017-11-27       Impact factor: 11.530

Review 2.  Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria.

Authors:  Elizabeth Ann Misch; Christopher Saddler; James Muse Davis
Journal:  Curr Infect Dis Rep       Date:  2018-03-19       Impact factor: 3.725

3.  Esx Paralogs Are Functionally Equivalent to ESX-1 Proteins but Are Dispensable for Virulence in Mycobacterium marinum.

Authors:  Rachel E Bosserman; Cristal Reyna Thompson; Kathleen R Nicholson; Patricia A Champion
Journal:  J Bacteriol       Date:  2018-05-09       Impact factor: 3.490

Review 4.  Type I Interferons in the Pathogenesis of Tuberculosis: Molecular Drivers and Immunological Consequences.

Authors:  Meg L Donovan; Thomas E Schultz; Taylor J Duke; Antje Blumenthal
Journal:  Front Immunol       Date:  2017-11-27       Impact factor: 7.561

Review 5.  Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases.

Authors:  Bas C Mourik; Erik Lubberts; Jurriaan E M de Steenwinkel; Tom H M Ottenhoff; Pieter J M Leenen
Journal:  Front Immunol       Date:  2017-04-05       Impact factor: 7.561

Review 6.  Sphingolipids Are Dual Specific Drug Targets for the Management of Pulmonary Infections: Perspective.

Authors:  Lalita Sharma; Hridayesh Prakash
Journal:  Front Immunol       Date:  2017-03-29       Impact factor: 7.561

7.  Streptococcal M protein promotes IL-10 production by cGAS-independent activation of the STING signaling pathway.

Authors:  Elin Movert; Julia Lienard; Christine Valfridsson; Therése Nordström; Bengt Johansson-Lindbom; Fredric Carlsson
Journal:  PLoS Pathog       Date:  2018-03-26       Impact factor: 6.823

8.  PGE2 displays immunosuppressive effects during human active tuberculosis.

Authors:  Joaquín Miguel Pellegrini; Candela Martin; María Paula Morelli; Julieta Aylen Schander; Nancy Liliana Tateosian; Nicolás Oscar Amiano; Agustín Rollandelli; Domingo Juan Palmero; Alberto Levi; Lorena Ciallella; María Isabel Colombo; Verónica Edith García
Journal:  Sci Rep       Date:  2021-06-30       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.